The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Integrating molecular testing into frontline treatment decisions in CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses incorporating molecular testing into the pretreatment workflow for patients with chronic lymphocytic leukemia (CLL). She highlights the importance of assessing IGHV status, del(17p) by FISH, and TP53 mutations to inform treatment decisions, and suggests incorporating these blood-based tests into standard pre-treatment checklists. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
